[PDF][PDF] Effect of weight-adjusted intermediate-dose versusfixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …

F Center - 2023 - factuel.univ-lorraine.fr
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …

[HTML][HTML] Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism …

S Zuily, B Lefèvre, O Sanchez, OE de Vendin… - …, 2023 - thelancet.com
Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …

[HTML][HTML] Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate COVID-19: Meta-analysis of randomized controlled …

J Ena, V Valls - Clinical and Experimental Medicine, 2023 - Springer
Background We carried out a meta-analysis since there is not enough evidence to
recommend for or against therapeutic-dose anticoagulation compared with …

[HTML][HTML] Thromboprophylaxis in COVID‐19: weight and severity adjusted intensified dosing

MM Engelen, C Vandenbriele, V Spalart… - Research and Practice …, 2022 - Elsevier
Background Venous thromboembolism (VTE) frequently occurs in hospitalized patients with
coronavirus disease 2019 (COVID‐19). The optimal dose of anticoagulation for …

[HTML][HTML] Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study

P Lamouche-Wilquin, L Perrin, M Pere, M Raymond… - Thrombosis …, 2023 - Springer
Background Patients with critical illness due to COVID-19 exhibit increased coagulability
associated with a high risk of venous thrombo-embolism (VTE). Data on prophylactic …

EVALUATION OF THROMBOEMBOLIC EVENTS AND ANTICOAGULANT STRATEGIES IN PATIENTS WITH COVID-19: A RETROSPECTIVE ANALYSIS

JLYND CRUZ, M Malesker, R Plambeck, C Destache… - Chest, 2021 - journal.chestnet.org
PURPOSE: The use of standard dose prophylaxis or higher doses of anticoagulation to
prevent venous thromboembolism (VTE) events in SARS-CoV-2 disease (COVID-19) is …

[HTML][HTML] Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial

M Blondon, S Cereghetti, J Pugin, C Marti… - Research and Practice …, 2022 - Elsevier
Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …

Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg od vs 40 mg bid The X-COVID19 Randomized Clinical Trial

N Morici, GM Podda, S Birocchi, L Bonacchini, M Merli… - medRxiv, 2021 - medrxiv.org
It is uncertain whether higher doses of anticoagulants than recommended for
thromboprophylaxis are necessary in COVID-19 patients hospitalized in general wards. This …

Efficacy and safety of escalated versus standard prophylactic anticoagulation in patients with Covid-19: A literature review and meta-analysis

CAL Arnesen - 2022 - munin.uit.no
Background: Coronavirus disease 2019 (COVID-19) is known to increase the risk of venous
thromboembolism (VTE), and studies have shown a three-fold increase in VTE-risk in …

[HTML][HTML] The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study

P Di Micco, A Tufano, G Cardillo, E Imbalzano… - Viruses, 2021 - mdpi.com
Background. According to recent guidelines, all hospitalized patients with COVID-19 should
receive pharmacological prophylaxis for venous thromboembolism (VTE), unless there are …